

Figure S3. Raw PPI analysis of each prepulse on %PPI.

Two-way ANOVA for time and treatment group were run for pp69, pp73, and pp81. Pp69 showed no significant influences of time ($F_{5,370}$ =0.8552 p=0.5115) or treatment ($F_{3,370}$ =0.5859 p=0.6262) and there was no significant interaction between the two variables ($F_{15,370}$ =1.150 p=0.3098) for this prepulse.

Pp73 showed a significant influence of time ($F_{5,370}$ =4.091 p=0.0013) but NSD for treatment or any interaction was seen, and post-hoc analysis (Bonferroni corrected) revealed no differences. Pp81 showed a significant influence of time ($F_{5,370}$ =25.63 p<0.0001) but NSD for treatment or any interaction was seen. Post-hoc analysis (Bonferroni corrected) revealed NSD for any other comparisons.

One-way ANOVA was used to analyze within group, between time points for each prepulse. Pp69 showed NSD for any treatment group (sham: F_{5,108}=1.446 p=0.2139; -shRNA: F_{5,84}=0.7478 p=0.5900; V2LMM: F_{5,126}=0.5833 p=0.7172; V3LMM: F_{5,126}=1.185 p=0.3206.

Pp73 showed NSD for any treatment group (sham: $F_{5,108}$ =1.697 p=0.1415; -shRNA: $F_{5,84}$ =0.4066 p=0.8429; V2LMM: $F_{5,126}$ =1.365 p=0.2420; V3LMM: $F_{5,126}$ =1.768 p=0.1240.

Pp81 showed differences in all four treatment groups. Sham: $F_{5,108}$ =3.409 p=0.0067, with post hoc (Tukey's HSD) showing significant difference in PPI between pre-op and week 6 (p<0.01). –shRNA: $F_{5,84}$ =3.585 p=0.0055 with post hoc showing pre-op vs. week 6 (p<0.05). V2LMM: $F_{5,126}$ =4.842 p=0.0004. post hoc pre-op vs. week 5 (p<0.001), pre-op vs. week 6 (p<0.05), week 3 vs. week 5 (p<0.05). V3LMM: $F_{5,126}$ =3.928 p=0.0024. post hoc pre-op vs. week 5 (p<0.05), pre-op vs. week 6 (p<0.05).

Numbers per group: sham: 20. -shRNA: 15. V2LMM: 20. V3LMM: 22